What Does Notch Therapeutics Do?

Total employees31
HeadquartersVancouver
Founded2018

Notch Therapeutics is a biotechnology company focused on developing and commercializing a pipeline of allogeneic, off-the-shelf, T cell therapies derived from induced pluripotent stem cells (iPSCs) for the treatment of cancer and other diseases. Their proprietary Engineered Thymic Niche (ETN™) platform recreates key aspects of thymic T cell development to generate T cells with desired therapeutic properties. Notch aims to deliver scalable, consistent, and cost-effective cell therapies.

Where Is Notch Therapeutics's Headquarters?

HQ Function

Serves as the main corporate office, housing executive leadership, core research and development activities, and administrative functions.

Notable Features:

Located in a modern office building in downtown Vancouver, providing access to advanced laboratory facilities and a vibrant biotech ecosystem.

Work Culture:

Characterized by a highly collaborative, innovative, and science-driven environment. Employees are typically passionate about advancing cell therapy and making an impact on patient lives. The culture emphasizes teamwork, scientific rigor, and a fast-paced approach typical of a growing biotech.

HQ Significance:

The Vancouver HQ is central to Notch's strategic direction, pioneering research in iPSC-derived T cell therapies, and fostering collaborations within Canada's life sciences hub.

Values Reflected in HQ: The headquarters reflects Notch's commitment to cutting-edge science, innovation, and a focused approach to developing transformative therapies.

Location:

Notch Therapeutics currently has a significant presence in North America, with key operational sites in Vancouver and Toronto, Canada, and Seattle, USA. These locations support the company's end-to-end capabilities, from foundational research and discovery to process development, manufacturing, and clinical trial planning. While current operations are North America-centric, their ambition to provide global 'off-the-shelf' therapies implies future expansion to support international clinical trials and commercialization.

Street Address:

410 West Georgia Street, Suite 1700

City:

Vancouver

State/Province:

British Columbia

Country:

Canada

Where Else Does Notch Therapeutics Operate Around the World?

Seattle, Washington/USA

Address: 2401 Elliott Avenue, Suite 400, Seattle, WA 98121, USA

To establish robust and scalable manufacturing processes for their allogeneic cell therapy candidates and to facilitate US-based clinical operations and collaborations.

Toronto, Ontario/Canada

Address: MaRS Centre, West Tower, 661 University Ave., Suite 465, Toronto, ON M5G 1M1, Canada

To drive innovation in iPSC differentiation and T cell engineering, and to foster strategic partnerships within one of Canada's largest biomedical research clusters.

Buying Intent Signals for Notch Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Notch Therapeutics? Meet the Executive Team

As of April 2025, Notch Therapeutics' leadership includes:

Chris Bond - Chief Executive Officer
Kam Fanaian - Chief Financial Officer
David Shook, MD - Chief Medical Officer
Peter Zandstra, PhD - Chief Scientific Officer & Co-Founder
Yvonne Yamanaka, PhD - Chief Operating Officer
Casey Case, PhD - Chief Business Officer

Who's Investing in Notch Therapeutics?

Notch Therapeutics has been backed by several prominent investors over the years, including:

Allogene Therapeutics
Lumira Ventures
CCRM Enterprises Holdings Ltd.
Accomplice
EcoR1 Capital
Casdin Capital
Samsara BioCapital
Amplitude Ventures
Genesys Capital

What Leadership Changes Has Notch Therapeutics Seen Recently?

Hire0
Exits0

In the past 12-15 months, Notch Therapeutics has made significant additions to its executive team, notably appointing a new Chief Financial Officer and Chief Medical Officer. No major executive departures have been publicly announced during this specific 12-month window.

New Appointments:

Kam Fanaian, Kam Fanaian was appointed as Chief Financial Officer, bringing extensive experience in biotech finance.
David Shook, MD, Dr. David Shook joined as Chief Medical Officer to lead clinical development strategies.

What Technology (Tech Stack) Is Used byNotch Therapeutics?

Discover the tools Notch Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Notch Therapeutics Email Formats and Examples

Notch Therapeutics likely uses common corporate email formats. The most probable formats are [first_initial][last]@notchtx.com or [first].[last]@notchtx.com.

[f][last]@notchtx.com or [first].[last]@notchtx.com

Format

jdoe@notchtx.com or jane.doe@notchtx.com

Example

80%

Success rate

What's the Latest News About Notch Therapeutics?

Business WireNovember 2, 2023

Notch Therapeutics Presents Preclinical Data at SITC 2023 Demonstrating Potential of Off-the-Shelf Gamma Delta T Cell Therapies Derived from its Proprietary Engineered Tissues Platform

Notch Therapeutics shared promising preclinical data for its iPSC-derived gamma delta (γδ) T cell candidates at the Society for Immunotherapy of Cancer (SITC) 2023. The data highlighted the ETN™ platform's ability to generate γδ T cells with potent anti-tumor activity....more

Business WireApril 18, 2023

Notch Therapeutics Strengthens Leadership Team with Key Appointments

Notch Therapeutics announced the appointment of Kam Fanaian as Chief Financial Officer and David Shook, M.D., as Chief Medical Officer. These appointments aim to bolster the company's leadership as it advances its pipeline....more

Business WireOctober 26, 2022

Allogene Therapeutics and Notch Therapeutics Announce Exclusive Collaboration and License Agreement for Induced Pluripotent Stem Cell (iPSC) AlloCAR T™ Therapies for Hematologic Malignancies

Allogene and Notch entered an exclusive collaboration to develop and commercialize iPSC-derived AlloCAR T™ therapies for initial targets in hematologic malignancies. Notch received an upfront payment and is eligible for milestones and royalties....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Notch Therapeutics, are just a search away.